India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
A federal judge has denied class‑certification in the high‑stakes Batton commission lawsuit, delivering a temporary win for NAR and major brokerages while leaving the door open for plaintiffs to try again. With as much as $3.6 billion in potential damages on the line and nearly 80% of the proposed class now disqualified due to conflicts with earlier settlements, the case stands at a pivotal moment. Real estate professionals nationwide — especially in Florida — should watch closely, as the ruling could shape the future of buyer‑agent compensation.
Florida homeowners are paying nearly double the national average for insurance, with premiums now reaching $5,838 a year and denied claims topping 40 percent. Residents report tripled rates, underpaid claims, and mounting financial strain, pushing lawmakers in Tallahassee to propose caps on rate hikes, tax breaks for storm‑proof upgrades, and tighter oversight of insurers. These developments are reshaping real estate and insurance conversations across the state as professionals brace for major industry shifts.
Berkshire County closed Q3 2025 with strong momentum as sales, dollar volume, and buyer competition all climbed year‑over‑year. Inventory showed slight improvement but remains far below demand, keeping the market tilted toward sellers. Single‑family homes and condos led the surge, while multifamily, land, and commercial sectors showed mixed performance. The region continues to stand out as one of New England’s most resilient real estate markets heading into 2026.
Florida homeowners now face the highest insurance burdens in the nation, with average premiums topping $5,800 per year—roughly $3,000 above the national average. As rates triple for some residents, more Floridians are skipping coverage altogether, while denied claims and slow payouts add to the frustration. With over 40 percent of claims closing with no payment and lawmakers battling over reform in Tallahassee, the crisis is reshaping budgets, homebuying decisions, and the real estate industry statewide.
Global capital is surging back into real estate—and this time, investors want more control. Colliers’ 2026 Global Investor Outlook reveals a major shift toward direct investments, joint ventures, and hands‑on strategies as money moves across North America, Europe, and the booming Asia‑Pacific markets. Data centers are now the top‑funded asset class, offices are staging a comeback, and adaptive reuse is reshaping cities worldwide. For real estate and finance professionals, the message is clear: opportunity is accelerating, and those with the right education and licensing will be at the center of the action.
The Fed’s recent rate cuts should have offered relief to commercial real estate—but long-term borrowing costs haven’t budged. While short‑term rates are falling, stubborn long‑term yields, broken deal math, and a trillion‑dollar refinancing wave are keeping the market frozen. For investors and professionals across Florida and the nation, understanding this disconnect is key to navigating the opportunities and risks emerging in today’s shifting CRE landscape.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
